Parkside Financial Bank & Trust Seagen Inc. Transaction History

Parkside Financial Bank & Trust

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$191.51 - $216.16 $383 - $432	2 Added 4.17%	50 $10,000
Q2 2023 Aug 15, 2023	BUY	$187.64 - $206.25 $375 - $412	2 Added 4.35%	48 $9,000
Q1 2023 May 04, 2023	SELL	$127.59 - $203.08 $7,782 - $12,387	-61 Reduced 57.01%	46 $9,000
Q4 2022 Feb 13, 2023	SELL	$117.37 - $139.17 $1,760 - $2,087	-15 Reduced 12.3%	107 $13,000
Q3 2022 Nov 01, 2022	BUY	$135.27 - $180.11 $13,932 - $18,551	103 Added 542.11%	122 $17,000
Q2 2022 Jul 13, 2022	SELL	$108.81 - $179.33 $3,917 - $6,455	-36 Reduced 65.45%	19 $3,000
Q1 2022 May 13, 2022	BUY	$119.61 - $157.85 $2,152 - $2,841	18 Added 48.65%	55 $8,000
Q4 2021 Feb 14, 2022	SELL	$142.57 - $190.86 $285 - $381	-2 Reduced 5.13%	37 $6,000
Q3 2021 Oct 29, 2021	BUY	$142.45 - $169.82 $854 - $1,018	6 Added 18.18%	39 $7,000
Q2 2021 Aug 06, 2021	SELL	$135.08 - $161.1 $270 - $322	-2 Reduced 5.71%	33 $5,000
Q1 2021 May 10, 2021	SELL	$137.51 - $190.8 $12,100 - $16,790	-88 Reduced 71.54%	35 $5,000
Q4 2020 Feb 09, 2021	BUY	$164.63 - $211.93 $20,249 - $26,067	123 New	123 $22,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Parkside Financial Bank & Trust, based on Form 13F filings with the SEC.

Stay updated on Parkside Financial Bank & Trust with notifications on news.